MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference

Rhea-AI Summary

MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET. The live chat can be accessed via B. Riley's website, with a replay available afterward on MiNK's Events and Presentations page. The conference, taking place on January 18-19, will showcase over 30 healthcare companies focusing on innovations in cancer treatment, featuring discussions by key opinion leaders in the field.

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 3^rd Annual B. Riley Securities Oncology Conference on January 18^th, at 11:00 AM ET.

Access to the live fireside chat is available at https://brileyoncology22.sequireevents.com/. Following the fireside chat, a replay will be available on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations.

B. Riley Securities 3rd Annual Oncology Conference, January 18-19, will feature over 30 SMiD cap healthcare companies focused on the development and commercialization of new medicines and key enabling technologies, cutting across multiple next-generation therapeutic modalities. The conference will feature KOL panel discussions with academic and industry leaders at the forefront of translational and clinical research underway with novel immunotherapy, cell therapy, and targeted oncology approaches, as well as imaging and radiation oncology initiatives, aimed at driving meaningful improvements to current standard of care for cancer patients.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT.

Contact

Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com

 

FAQ

What is MiNK Therapeutics doing at the 3rd Annual B. Riley Securities Oncology Conference on January 18?

MiNK Therapeutics will have Dr. Jennifer Buell, President and CEO, participate in a fireside chat at the conference on January 18 at 11:00 AM ET.

How can I access the fireside chat by MiNK Therapeutics at the B. Riley Securities conference?

The live fireside chat can be accessed on the B. Riley Oncology Conference website, and a replay will be available on MiNK's Events and Presentations page afterward.

What is the focus of the B. Riley Securities Oncology Conference?

The conference features more than 30 healthcare companies and includes discussions on advancements in cancer treatment, including novel immunotherapy and cell therapy.

When is the 3rd Annual B. Riley Securities Oncology Conference taking place?

The conference will take place on January 18-19, 2023.

What type of therapies is MiNK Therapeutics developing?

MiNK Therapeutics is developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.